Habitual	habitual	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
risk	risk	O	O	O	O
factor	factor	O	O	O	O
for	for	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
:	:	O	O	O	O
a	a	O	O	O	O
comparison	comparison	O	O	O	O
with	with	O	O	O	O
phenacetin	phenacetin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Six	six	O	O	O	O
epidemiologic	epidemiologic	O	O	O	O
studies	studies	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
United	united	O	O	O	O
States	states	O	O	O	O
and	and	O	O	O	O
Europe	europe	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
habitual	habitual	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
phenacetin	phenacetin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
and	and	O	O	O	O
end-stage	end-stage	O	O	O	O
renal	renal	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
(	(	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
relative	relative	O	O	O	O
risk	risk	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
range	range	O	O	O	O
of	of	O	O	O	O
4	4	O	O	O	O
to	to	O	O	O	O
19	19	O	O	O	O
.	.	O	O	O	O

As	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
and	and	O	O	O	O
other	other	O	O	O	O
studies	studies	O	O	O	O
,	,	O	O	O	O
phenacetin	phenacetin	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
now	now	O	O	O	O
been	been	O	O	O	O
withdrawn	withdrawn	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
market	market	O	O	O	O
in	in	O	O	O	O
most	most	O	O	O	O
countries	countries	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
three	three	O	O	O	O
case	case	O	O	O	O
control	control	O	O	O	O
studies	studies	O	O	O	O
,	,	O	O	O	O
one	one	O	O	O	O
each	each	O	O	O	O
in	in	O	O	O	O
North	north	O	O	O	O
Carolina	carolina	O	O	O	O
,	,	O	O	O	O
northern	northern	O	O	O	O
Maryland	maryland	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
West	west	O	O	O	O
Berlin	berlin	O	O	O	O
,	,	O	O	O	O
Germany	germany	O	O	O	O
,	,	O	O	O	O
showed	showed	O	O	O	O
that	that	O	O	O	O
habitual	habitual	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
also	also	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
and	and	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
relative	relative	O	O	O	O
risk	risk	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
range	range	O	O	O	O
of	of	O	O	O	O
2	2	O	O	O	O
to	to	O	O	O	O
4	4	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
studies	studies	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
both	both	O	O	O	O
phenacetin	phenacetin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
contribute	contribute	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
burden	burden	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
latter	latter	O	O	O	O
being	being	O	O	O	O
somewhat	somewhat	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
former	former	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
apparent	apparent	O	O	O	O
difference	difference	O	O	O	O
in	in	O	O	O	O
risk	risk	O	O	O	O
may	may	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
nephrotoxic	nephrotoxic	O	DISEASE	OTHERS	I
potential	potential	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drugs	drugs	O	O	O	O
themselves	themselves	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
lower	lower	O	O	O	O
relative	relative	O	O	O	O
risk	risk	O	O	O	O
would	would	O	O	O	O
be	be	O	O	O	O
expected	expected	O	O	O	O
for	for	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
if	if	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
drugs	drugs	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
analgesics	analgesics	O	O	O	O
was	was	O	O	O	O
higher	higher	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
either	either	O	O	O	O
agent	agent	O	O	O	O
alone	alone	O	O	O	O
.	.	O	O	O	O

Thus	thus	O	O	O	O
,	,	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
used	used	O	O	O	O
both	both	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
agent	agent	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
analgesics	analgesics	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
phenacetin	phenacetin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
available	available	O	O	O	O
only	only	O	O	O	O
in	in	O	O	O	O
combinations	combinations	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
possibility	possibility	O	O	O	O
that	that	O	O	O	O
habitual	habitual	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
acetaminophen	acetaminophen	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
increases	increases	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
ESRD	esrd	O	DISEASE	OTHERS	I
has	has	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
clearly	clearly	O	O	O	O
demonstrated	demonstrated	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
can	can	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
dismissed	dismissed	O	O	O	O
.	.	O	O	O	O

